Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Economic Evaluation of Anastrozole Versus...
Journal article

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore

Abstract

OBJECTIVES: In Singapore, breast cancer is the leading female malignancy and its incidence has increased threefold over the past decades. For treatment of postmenopausal, hormone receptor positive early stage breast cancer, tamoxifen or aromatase inhibitors such as anastrozole are prescribed either as first-line therapy or sequentially. Currently, anastrozole is patented with a higher drug cost compared with tamoxifen. Hence, the aim of this …

Authors

Shih V; Chan A; Xie F; Ko Y

Journal

Value in Health Regional Issues, Vol. 1, No. 1, pp. 46–53

Publisher

Elsevier

Publication Date

May 2012

DOI

10.1016/j.vhri.2012.03.013

ISSN

2212-1099